Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug AdministrationEP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug dev.
Ellipses Pharma: Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.